Oncolytics Biotech, Inc (ONCY) concluded trading on Wednesday at a closing price of $0.82, with 32.23 million shares of worth about $26.43 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -23.36% during that period and on January 15, 2025 the price saw a gain of about 1.23%. Currently the company’s common shares owned by public are about 77.07M shares, out of which, 76.02M shares are available for trading.
Stock saw a price change of -10.33% in past 5 days and over the past one month there was a price change of -1.88%. Year-to-date (YTD), ONCY shares are showing a performance of -10.26% which decreased to -32.79% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.71 but also hit the highest price of $1.53 during that period. The average intraday trading volume for Oncolytics Biotech, Inc shares is 468.20K. The stock is currently trading -7.37% below its 20-day simple moving average (SMA20), while that difference is down -12.91% for SMA50 and it goes to -20.38% lower than SMA200.
Oncolytics Biotech, Inc (NASDAQ: ONCY) currently have 77.07M outstanding shares and institutions hold larger chunk of about 1.62% of that.
The stock has a current market capitalization of $63.20M and its 3Y-monthly beta is at 1.27. It has posted earnings per share of -$0.27 in the same period. It has Quick Ratio of 2.99 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ONCY, volatility over the week remained 8.58% while standing at 9.25% over the month.
Analysts are in expectations that Oncolytics Biotech, Inc (ONCY) stock would likely to be making an EPS of -0.13 in the current quarter, while forecast for next quarter EPS is 0 and it is -0.47 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.14 which is -0.13 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.11 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -1.84% while it is estimated to decrease by -10.39% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Maxim Group on October 06, 2022 offering a Buy rating for the stock and assigned a target price of $3 to it. Coverage by H.C. Wainwright stated Oncolytics Biotech, Inc (ONCY) stock as a Buy in their note to investors on February 17, 2021, suggesting a price target of $15 for the stock.
